These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15337242)

  • 1. The molecular determinants of estrogen receptor pharmacology.
    McDonnell DP
    Maturitas; 2004 Aug; 48 Suppl 1():S7-12. PubMed ID: 15337242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
    Dutertre M; Smith CL
    J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular mechanism of tissue-specific actions of sex steroid hormones and SERM for bone remodeling].
    Kato S
    Clin Calcium; 2005 May; 15(5):825-30. PubMed ID: 15876746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estrogen receptor subtypes and the regulatory effect of receptor ligand binding on gene transcription].
    An SJ; Zhang YX
    Sheng Li Ke Xue Jin Zhan; 2002 Oct; 33(4):309-12. PubMed ID: 12650065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
    Mukherjee S; Saha A; Roy K
    Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
    Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
    Nilsson S; Koehler KF
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in estrogen receptor modulators.
    Henke BR; Heyer D
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):437-48. PubMed ID: 16022180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer, estrogen receptor and ligands.
    Bai Z; Gust R
    Arch Pharm (Weinheim); 2009 Mar; 342(3):133-49. PubMed ID: 19274700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.
    Richardson TI; Norman BH; Lugar CW; Jones SA; Wang Y; Durbin JD; Krishnan V; Dodge JA
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3570-4. PubMed ID: 17485205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist activity of the 3-hydroxy metabolites of tibolone through the oestrogen receptor in the mouse N20.1 oligodendrocyte cell line and normal human astrocytes.
    Guzmán CB; Zhao C; Deighton-Collins S; Kleerekoper M; Benjamins JA; Skafar DF
    J Neuroendocrinol; 2007 Dec; 19(12):958-65. PubMed ID: 18001325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.
    Jordan VC
    J Med Chem; 2003 Mar; 46(6):883-908. PubMed ID: 12620065
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogens and SERMs in coronary heart disease.
    Regitz-Zagrosek V; Wintermantel TM; Schubert C
    Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling by estrogens.
    Cheskis BJ; Greger JG; Nagpal S; Freedman LP
    J Cell Physiol; 2007 Dec; 213(3):610-7. PubMed ID: 17886255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective estrogen receptor modulators: mechanisms of action and their tissue selectivity].
    Azuma K; Inoue S
    Clin Calcium; 2004 Oct; 14(10):12-26. PubMed ID: 15577127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.